Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-24-098582
Filing Date
2024-08-19
Accepted
2024-08-19 16:33:42
Documents
73
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A eldn-20240331.htm   iXBRL 10-Q/A 1679762
2 EX-31.3 eldn-ex31_3.htm EX-31.3 14364
3 EX-31.4 eldn-ex31_4.htm EX-31.4 14482
4 EX-32.3 eldn-ex32_3.htm EX-32.3 9011
5 EX-32.4 eldn-ex32_4.htm EX-32.4 9073
  Complete submission text file 0000950170-24-098582.txt   7818366

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eldn-20240331.xsd EX-101.SCH 1118246
75 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20240331_htm.xml XML 1374086
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-36620 | Film No.: 241221098
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)